Pinteon Therapeutics is a biotechnology company founded in 2014 and based in Newton, Massachusetts. The company's mission is to pioneer therapies targeting Pin1 to normalize disease processes and enhance patient outcomes in critical health conditions. Pin1, a central regulator in cancer progression, CNS, and autoimmune conditions, plays a critical role. Pinteon aims to develop novel therapeutics that either inhibit or activate Pin1 to address significant unmet medical needs.
Recently, the company secured a $28.09M Series B investment on 11 January 2022, signaling investor confidence in their innovative approach. This capital injection will likely facilitate the advancement of Pinteon's therapeutic development and research efforts. With a focus on the biotechnology and healthcare industries, Pinteon Therapeutics is well-positioned to make a meaningful impact in the field of disease treatment and patient care.
